Protocols · Cognitive
The two peptides are frequently co-administered in Russian clinical practice, and there are combination reports, but no controlled trial has isolated the effect of the pairing. The figures below are the two source literatures placed side by side.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Acute stroke arms use 12–18 mg per day of a 1% solution, an entirely different scale.
The published protocols express this in drops per nostril rather than micrograms.
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
Semax · 10 mg Vial
This Semax dosage chart explains how a 10 mg vial can be calculated for intranasal research with a verified 0.10 mL metered actuator. Published human Semax studies primarily used intranasal drops or measured intranasal solution. A measured 5 mL final volume provides 200 mcg per spray, while a measured 10 mL final volume provides 100 mcg per spray.
| Measured Final Volume | Vehicle Added After Transfer | Final Concentration | Per Verified 0.10 mL Spray |
|---|---|---|---|
| 5.0 mL | About 2.0 mL | 2,000 mcg/mL | 200 mcg<br>50 nominal sprays |
| 10.0 mL | About 7.0 mL | 1,000 mcg/mL | 100 mcg<br>100 nominal sprays |
Selank · 10 mg Vial
This Selank dosage chart explains how a 10 mg vial can be calculated for intranasal research with a verified 0.10 mL metered actuator. Published human Selank studies primarily used intranasal drops or measured intranasal solution. A measured 5 mL final volume provides 200 mcg per spray, while a measured 10 mL final volume provides 100 mcg per spray.
| Measured Final Volume | Vehicle Added After Transfer | Final Concentration | Per Verified 0.10 mL Spray |
|---|---|---|---|
| 5.0 mL | About 2.0 mL | 2,000 mcg/mL | 200 mcg<br>50 nominal sprays |
| 10.0 mL | About 7.0 mL | 1,000 mcg/mL | 100 mcg<br>100 nominal sprays |
Blend vials should state the mass of each peptide. Because both are dosed by solution percentage in the literature, the concentration you prepare matters more here than the vial mass.
Open the reconstitution calculatorNo peer-reviewed primary literature reporting administered quantities exists for this item. Anything circulating online about quantities is anecdote rather than evidence, and this page will not reproduce it. The database links below are kept so you can check for yourself as new work is published.
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.
